(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 June 2020 (04.06.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/113194 A3

(51) International Patent Classification:
A61K 35/17 (2015.01) *A61P 35/00* (2006.01)
A61K 39/00 (2006.01)

(21) International Application Number:
PCT/US2019/063889

(22) International Filing Date:
29 November 2019 (29.11.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/774,164	30 November 2018 (30.11.2018)	US
62/776,415	06 December 2018 (06.12.2018)	US
62/847,926	14 May 2019 (14.05.2019)	US
62/854,945	30 May 2019 (30.05.2019)	US
62/890,600	22 August 2019 (22.08.2019)	US
62/931,204	05 November 2019 (05.11.2019)	US

(71) Applicant: **JUNO THERAPEUTICS, INC.** [US/US]; 400 Dexter Ave. N, Suite 1200, Seattle, Washington 98109-4703 (US).

(72) Inventors: **ALBERTSON, Tina**; c/o Juno Therapeutics, Inc., 400 Dexter Ave. N, Suite 1200, Seattle, Washington 98109-4703 (US). **GARCIA, Jacob Randolph**; c/o Juno Therapeutics, Inc., 400 Dexter Ave. N, Suite 1200, Seattle, Washington 98109-4703 (US). **GILBERT, Mark**; c/o Juno Therapeutics, Inc., 400 Dexter Ave. N, Suite 1200, Seattle, Washington 98109-4703 (US). **LI, He**; c/o Juno Therapeutics, Inc., 400 Dexter Ave. N, Suite 1200, Seattle, Washington 98109-4703 (US). **SUTHERLAND, Claire**; c/o Juno Therapeutics, Inc., 400 Dexter Ave. N, Suite 1200, Seattle, Washington 98109-4703 (US).

(74) Agent: **AHN, Sejin** et al.; Morrison & Foerster LLP, 12531 High Bluff Drive, Suite 100, San Diego, California 92130-2040 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
23 July 2020 (23.07.2020)

(54) Title: METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY

(57) Abstract: Provided are adoptive cell therapy involving the administration of doses of cells for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a large B cell lymphoma, such as a diffuse large B-cell lymphoma (DLBCL). Also provided are methods of assessing the risk of developing a toxicity related to a cell therapy, and methods of identifying subjects and methods of treating subjects based on the assessment of risks.

WO 2020/113194 A3